AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended)

A compound selected from the group consisting of all possible stereoisomers of a compound of the formula



I

either R_1 is hydrogen or methyl and R_2 is selected from the group consisting of

$-CH_2-CH_2NHCH_3$,



~~$-CH_2CHCH_3NH_2$,~~

$-CH_2CHCH_2NH_2$,








-$CHCH_3CH_2NH_2$, -(CH2)aOH where a is an integer of 1 to 8, -$(CH_2)_b$ -C≡N where b is an integer of 1 to 8, -$CHCH_3C_6H_5$, -(CH_2)-$C(CH_3)_2NHCOCF_3$, and –$CHCH_3(CH_2)$dOH where d is an integer of 1 to 8,

R_3 is selected from the group consisting of hydrogen, methyl and hydroxyl,

R_4 is hydrogen or hydroxyl,

R is selected from the group consisting of a) alkyl and cycloalkyl of up to 30 carbon atoms, optionally containing at least one heteroatom, b) at least one heterocycle, c) ~~and~~ acyl or cyclic acyl of up to 30 carbon atoms optionally containing at least one heteroatom, and d) at least one heterocycle,

T is selected from the group consisting of hydrogen, methyl, -CH_2CONH_2, –CH_2-C≡N, and -$(CH_2)_2NH_2$,

Y is selected from the group consisting of hydrogen, hydroxyl, halogen and –OSO_3H or a salt thereof,

W is hydrogen or OH,

Z is hydrogen or methyl and its non-toxic, pharmaceutically acceptable acid addition salt.

Claim 2 (previously presented)

The compound of claim 1 in which T is hydrogen.

Claim 3 (previously presented)

The compound of claim 1 in which W is hydrogen.

Claim 4 (previously presented)

The compound of claim 1 in which Z is methyl.

Claim 5 (previously presented)

The compound of claim 1 in which Y is hydrogen.

Claim 6 (previously presented)

The compound of claim 1 in which R_3 is methyl.

Claim 7 (previously presented)

The compound of claim 1 in which R_4 is hydroxyl.

Claim 8 (previously presented)

The compound of claim 1 in which R is selected from the group consisting of





































Claim 9 (previously presented)

The compound of claim 8 in which R is



Claim 10 (previously presented)

The compound of claim 8 in which R is



Claim 11 (previously presented)

The compound of claim 1 in which R_1 is hydrogen.

Claim 12 (cancelled)

Claim 13 (currently amended)

The compound of claim 1 in which R_2 is selected from the group consisting of

~~$CH_2C(CH_2)_2NH_2$, CH_2CHNH_2, and $CHCH_2NH_2$~~ (with CH_3 and CH_3)



$-CH_2-C(CH_3)_2-NH_2$, $-CH_2-CH(CH_3)-NH_2$, and $-CH(CH_3)-CH_2NH_2$.

Claim 14 (previously presented)

The compound of claim 1 in which R_2 is



Claim 15 (currently amended)

The compound of claim 1 is 1-[4-[[(1H-benzimidazol-2-yl)-methyl]-amino]-N2-[[4"-(pentyloxy) ~~[1,2':4', 1"~~ [1,2':4', 1" - terphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]5-L-serine-~~echinocandine~~ echinocandin B trifluoroacetate (isomer B) .

Claim 16 - 18 (cancelled)

Claim 19 (previously presented)

An antifungal composition comprising an antifungally effective amount of a compound of claim 15 and an inert pharmaceutical carrier.

Claim 20 (previously presented)

A method of treating fungal infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antifungally effective amount of a compound of claim 15.